Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. Aug 26, 2014; 5(3): 286-300
Published online Aug 26, 2014. doi: 10.4331/wjbc.v5.i3.286
Published online Aug 26, 2014. doi: 10.4331/wjbc.v5.i3.286
In 2014, can we do better than CA125 in the early detection of ovarian cancer?
Joshua G Cohen, Matthew White, Ana Cruz, Robin Farias-Eisner, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Los Angeles Medical Center, Los Angeles, CA 90095, United States
Author contributions: Cohen JG, White M and Cruz A performed research and acquisition of data; Cohen JG, White M, Cruz A and Farias-Eisner R performed synthesis of data, developed tables and figures, and authored manuscript.
Correspondence to: Robin Farias-Eisner MD, PhD, Department of Obstetrics and Gynecology, University of California, Los Angeles Medical Center, Peter Morton Medical Building, 200 Medical Plaza, Suite 220, Los Angeles, CA 90095, United States. rfeisner@mednet.ucla.edu
Telephone: +1-310-2068914 Fax: +1-310-2062057
Received: January 17, 2014
Revised: March 12, 2014
Accepted: May 14, 2014
Published online: August 26, 2014
Revised: March 12, 2014
Accepted: May 14, 2014
Published online: August 26, 2014
Core Tip
Core tip: Ovarian cancer is a lethal gynecologic malignancy with five-year survival of only 20% to 40% for advanced stage disease. Detection at an early stage would likely have significant impact on mortality rate. Advances in high throughput screening with the human “-omes” including the proteome, genome, metabolome, and transcriptome are now available in various packaged forms. To make progress in screening we need greater emphasis on prospective collection of patient specimens, integration of high throughput screening, and use of molecular heterogeneity in biomarker discovery.